Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Smith Mark Alan					2. Issuer Name and Ticker or Trading Symbol <u>VistaGen Therapeutics</u> , <u>Inc.</u> [ VTGN ]							eck all applic Directo Y Officer	or (give title	10% Ov Other (s	ner	
(Last) (First) (Middle) C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 11/09/2016							CHIEF MEDICAL OFFICER				
343 ALL	ERTON AV	VENUE .		L												
(Street) SOUTH SAN FRANCISCO		A 94080		4	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)													
		Tab	le I - Non-I	Derivati	ve Se	curities	s Ac	quired, Di	sposed o	f, or Be	neficiall	y Owned				
Date				. Transactio Date Month/Day/	Year)   I	2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Ins	on Disposed			Beneficia Owned F Reported	es Formally (D) (Following (I) (I	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code V	Amount	mount (A) or (D)		Transact (Instr. 3 a				
		-	Table II - De (e.					uired, Dis s, options,				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code	saction (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$3.8	11/09/2016		A		80,000		(1)	11/09/2026	Common Stock	80,000	\$0	80,000	D		

## **Explanation of Responses:**

1. Options vest monthly over a period of three years commencing November 9, 2016.

/s/ Jerrold D. Dotson, Attorney-11/10/2016 in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.